Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction
Summary
The ADMIRAL (Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction) study demonstrated that early administration of abciximab in patients with ST elevation acute myocardial infarction prior to PCI improves clinical outcomes but no specifically designed randomized study has addressed the issue of early upstream use of GP IIb/IIIa inhibitors in ST elevation acute myocardial infarction who are undergoing PCI, especially in the era of routine pretreatment with 600 mg of clopidogrel. Therefore, the objective of the randomized ECLAT-STEMI study was to assess the hypothesis that the early upstream use of Clotinab is a useful therapy in patients with ST elevation MI undergoing PCI compared to "provisional use", even after pretreatment with a 600-mg loading dose of clopidogrel.
Timeline
- Start
- 2007-07
- Primary completion
- 2009-12
- Completion
- 2009-12
Outcome
Missed primary endpoint
paper There was no significant difference in the events that occurred in 40 patients (10.2%) in the upstream arm and 55 patients (14.0%) PMID 22146757 ↗
paper (odds ratio 0.70, 95% confidence interval 0.45-1.08). PMID 22146757 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clotinab | Unknown | 0.125 ug/kg | Intravenous |